PAVmed Secures $45M in Preferred Stock & Senior Note Financing, Clears Legacy Debt, Adds $7.7M Net Cash

summarizeSummary

PAVmed Inc. closed a $30 million Series D Convertible Preferred Stock offering with warrants and a $15 million senior secured note, using proceeds to redeem all outstanding Series C Preferred Stock and refinance convertible debt, resulting in $7.7 million in net cash proceeds.

check_boxKey Events

• Secured $30 Million in Series D Preferred Stock

  PAVmed issued 30,000 shares of newly designated Series D Convertible Preferred Stock for an aggregate purchase price of $30 million. This includes warrants exercisable for an additional 30,000 shares of Series D Preferred Stock, callable upon a positive draft Medicare local coverage determination for Lucid Diagnostics' EsoGuard product.

• Established New $15 Million Senior Secured Note

  The company concurrently issued a $15 million senior secured note to an existing investor, accruing interest at 15.0% per annum and maturing in February 2029. The note has a conversion price of $450.00 per share.

• Redeemed All Series C Preferred Stock and Refinanced Debt

  Proceeds from the new financings were used to redeem all 16,962 outstanding shares of Series C Preferred Stock and refinance $8,414,890 in principal and interest of its Senior Secured Convertible Note issued in September 2022, totaling approximately $22.3 million in cash payments.

• Added $7.7 Million in Net Cash Proceeds

  After the redemptions and refinancing, the company retained approximately $7.7 million in net cash proceeds for general working capital purposes, significantly strengthening its balance sheet.

auto_awesomeAnalysis

This 8-K details a highly significant and complex financing transaction for PAVmed, a micro-cap company. The $30 million Series D Convertible Preferred Stock and $15 million senior secured note represent a substantial capital injection relative to the company's size. While the transaction is highly dilutive, with the Series D Preferred Stock convertible at a significant discount to the current market price, it simultaneously addresses a critical issue by eliminating a legacy capital structure overhang from previously outstanding convertible securities. The net cash proceeds of $7.7 million materially strengthen the balance sheet and provide crucial operating runway. This strategic move, following a recent regain of Nasdaq compliance, positions the company with a cleaner capital structure, which management describes as a "transformational positive outcome" to support its diversified medical technology operations and subsidiaries like Lucid Diagnostics and Veris Health.